

January 12, 2015

Genetic Technologies Limited – Ratio Change and Reverse Split

DR CUSIP: 37185R109

DR ISIN: US37185R1095

DR Ticker Symbol: GENE

Ratio (DS: Underlying Shares): 1:30

The Bank of New York Mellon, at the direction of Genetic Technologies Limited (the “Company”), is announcing a ratio change on the Depositary Receipt (“DR”) program from one (1) Depositary Share (“DS”) representing thirty (30) Ordinary shares to one (1) DS representing one hundred fifty (150) Ordinary shares.

As a result, BNY Mellon will effect a reverse stock split on the Genetic Technologies Limited Depositary Receipt (“DR”) program. Effective January 20, 2015, DR holders of Genetic Technologies Limited are required on a mandatory basis to surrender their DR(s) for cancellation and exchange their “Old” DRs (CUSIP 37185R109) for “new” DRs (CUSIP 37185R208). DR holders will receive 1 “New” Depositary Share (DS) (CUSIP 37185R208) for every 5 “Old” DSs (CUSIP 37185R109). Only whole DSs will be distributed.

BNY Mellon will attempt to sell any fractional DSs and distribute the cash proceeds to DR holders.

Note below the timetable for the reverse stock split:

Effective date:	January 20, 2015
Old CUSIP:	37185R109
Old Ratio:	1 DS : 30 Ordinary shares
Exchange Ratio:	1 new DS for every 5 old DSs
New CUSIP:	37185R208
New Ratio:	1 DS : 150 Ordinary shares

Please note: A ratio change may impact the fees payable by DR investors.

BNY Mellon’s books will be closed for all issuance and cancellation transactions as of the close of business January 16, 2015.

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

<i>New York</i>	<i>London</i>	<i>Hong Kong</i>
Ravi Davis	Damon Rowan	Herston Powers
Richard J Maehr	Vice President	Vice President
+1 212 815-2267	+44 207 163 7511	+852 2 840 9868
Adrdesk@bnymellon.com	damon.rowan@bnymellon.com	Herston.powers@bnymellon.com

BNY Mellon collects fees from DR holders pursuant to the terms and conditions of the DRs and the deposit agreement under which they are issued. From time to time, BNY Mellon may make payments to the issuer to reimburse and / or share revenue from the fees collected from DR holders, or waive fees and expenses to the issuer for services provided, generally relating to costs and expenses arising out of establishment and maintenance of the DR program. BNY Mellon as depositary may use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions. The corporate action details are provided for informational purposes only. BNY Mellon does not warrant or guarantee the accuracy or completeness, and does not undertake any obligation to update or amend, this information or data. We provide no advice, recommendation or endorsement with respect to any company or security. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy Securities.